Log in to save to my catalogue

Real‐world data on the efficacy and safety of immune‐checkpoint inhibitors in elderly patients with...

Real‐world data on the efficacy and safety of immune‐checkpoint inhibitors in elderly patients with...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e841a5a350844541b0287c7aee9ab30b

Real‐world data on the efficacy and safety of immune‐checkpoint inhibitors in elderly patients with non‐small cell lung cancer

About this item

Full title

Real‐world data on the efficacy and safety of immune‐checkpoint inhibitors in elderly patients with non‐small cell lung cancer

Publisher

United States: John Wiley & Sons, Inc

Journal title

Cancer medicine (Malden, MA), 2023-05, Vol.12 (10), p.11525-11541

Language

English

Formats

Publication information

Publisher

United States: John Wiley & Sons, Inc

More information

Scope and Contents

Contents

Purpose
Immune‐checkpoint inhibitors (ICIs) are effective against advanced non‐small cell lung cancer (NSCLC). However, whether the efficacy and safety of ICI treatment in elderly patients are similar to those in younger patients is unclear. This study was designed to address this question.
Methods
We enrolled patients who received ICI mon...

Alternative Titles

Full title

Real‐world data on the efficacy and safety of immune‐checkpoint inhibitors in elderly patients with non‐small cell lung cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_e841a5a350844541b0287c7aee9ab30b

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e841a5a350844541b0287c7aee9ab30b

Other Identifiers

ISSN

2045-7634

E-ISSN

2045-7634

DOI

10.1002/cam4.5889

How to access this item